Redcare Pharmacy Reports Q3 Revenue Growth of 18% to EUR 847 Million
Redcare Pharmacy reported nine-month revenue of EUR 2.55 billion, up 19%, and adjusted EBITDA of EUR 28.7 million, up 68%. It confirmed full-year 2026 guidance for 16%–18% revenue growth and a 2.5%–3.0% adjusted EBITDA margin.
Redcare Pharmacy N.V. reported strong performance for the third quarter of 2026, achieving a net profit for the second consecutive quarter. Group revenue grew 18% year-over-year to EUR 847 million, while nine-month revenue reached EUR 2.55 billion, up 19%. The growth was primarily driven by a 31% increase in prescription (Rx) revenue, with Rx Germany specifically seeing a 56% surge.
Adjusted EBITDA rose 68% to EUR 28.7 million, resulting in a margin of 3.4%, up 1.0 percentage point from the previous year. Additionally, the company confirmed its full-year 2026 guidance, maintaining expectations for 16% to 18% total revenue growth and an adjusted EBITDA margin between 2.5% and 3.0%.